MedPath

Intracoronary Hypothermia as a Prevention of Reperfusion Injury in Myocardial Infarction.

Not Applicable
Recruiting
Conditions
Reperfusion Injury
Myocardial Infarction
ST-Elevation Myocardial Infarction (STEMI)
Microvascular Occlusion
Interventions
Other: Standard percutaneous coronary intervention
Procedure: Intracoronary hypothermia
Registration Number
NCT06567249
Lead Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Brief Summary

Acute myocardial infarction with ST segment elevation is often accompanied by a totally occluded coronary artery. Which has deleterious effects on heart muscle. Primary percutaneous coronary intervention is the most effective mode of treatment for ST-elevation myocardial infarction (STEMI) patients. Despite the restoration of the blood flow, 30-60% of patients develop microvascular obstruction, which lowers the effects of the coronary blood flow restoration. The most advanced coronary microvascular obstruction presents as a no-reflow phenomenon, which is an abrupt deceleration or absence of coronary flow following stent implantation. Several pharmacological treatments have been proposed, as well as deferred stenting, but none of them really helped. Thus, new ways of alleviating coronary obstruction are warranted. One of the new ways of mitigating the reperfusion injury is intracoronary hypothermia, which showed to be safe on a handful of patients in small series. In the animal studies, intracoronary hypothermia demonstrated a protective effect in terms of reducing infarct area. But clinical studies failed to reproduce the protective effects of intracoronary hypothermia. Thus, our study, using a modified hypothermia protocol, will test the hypothermia hypothesis.

Detailed Description

The study aims to find the most effective methods for the prevention and treatment of microvascular obstruction and reperfusion injury, studying the pathophysiological mechanisms of the development of this complication is of key importance. Many of these mechanisms are now known. In particular, the risk of developing microvascular obstruction is directly proportional to the duration of coronary artery occlusion, the degree of platelet aggregation activity, and blood viscosity and is higher in patients with massive thrombosis of the ischemic artery during percutaneous coronary intervention, which suggests a significant contribution to the development of microembolization during mechanical thrombus fragmentation. Despite all the collected data, there is no effective mode of reperfusion injury prophylaxis. Thus, it is necessary to explore new ways of minimizing reperfusion injury during primary percutaneous coronary intervention. The goal of our study is to determine the safety and effectiveness of intracoronary hypothermia. All patients who meet the eligibility criteria for this study will be randomized in a 1:1 ratio to receive intracoronary hypothermia with subsequent percutaneous coronary intervention or a standard revascularization strategy. The total number of patients planned to be recruited is 60. The study was approved by the local ethics committee. The intracoronary hypothermia group will receive 4°C normal saline with an infusion rate of 5 ml/min for 5 minutes through the inflated over-the-wire balloon, followed by an infusion of 4°C normal saline for 15 minutes with the same infusion rate of 5 ml per minute through the deflated over-the-wire balloon. After that, standard percutaneous coronary intervention is performed. The control group will receive only the standard percutaneous coronary intervention procedure.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Acute ST-elevation myocardial infarction
  • Time from onset of symptoms less than 12 hours
  • Given informed consent
Exclusion Criteria
  • Contraindication to MRI
  • Cardiogenic shock
  • Conduction disturbance: Atrioventricular block: 2nd and 3rd degree. SA block.
  • Sick sinus syndrome requiring implantable pacemaker
  • Pulmonary edema
  • Active inflammatory condition
  • Active chemo/radiation therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Conventional percutaneous coronary interventionStandard percutaneous coronary interventionThe group will receive standard percutaneous coronary intervention.
Intracoronary hypothermiaIntracoronary hypothermiaSelective intracoronary hypothermia starts by advancing the coronary guidewire beyond the occlusion of the culprit coronary vessel with subsequent over-the-wire balloon inflation at 5 atm at the site of the occlusion. Then, the guidewire is removed, and the infusion pump is connected to the over-the-wire balloon. Normal saline infusion starts with an infusion rate of 5 ml per minute and a duration of 5 minutes. The temperature of the saline is 4 °C. After that, the over-the-wire balloon is deflated, and infusion continues for 15 minutes at the same temperature and infusion rate of 5 mL per minute, followed by the standard percutaneous coronary intervention.
Primary Outcome Measures
NameTimeMethod
Microvascular obstruction (percent)7 days

Microvascular obstruction is expressed as a percentage of total myocardium mass revealed by the cardiac magnetic resonance imaging with late gadolinium enhancement at day seven.

Infarct size (percent)7 days

The primary endpoint is the infarct size, expressed as a percentage of total myocardium mass, revealed by the cardiac magnetic resonance imaging with late gadolinium enhancement after seven days.

Myocardial hemorrhage (percent)7 days

Myocardial hemorrhage extent is visualized by T2-weighted sequences on cardiac magnetic resonance imaging and expressed as a percentage of total myocardium mass.

Secondary Outcome Measures
NameTimeMethod
Ejection fraction (percent)10 days

Ejection fraction is measured by echocardiography and expressed as a percentage (Simpson's method).

Wall motion score index (score)10 days

Wall motion score index (score) measured by echocardiography at day 10.

Trial Locations

Locations (1)

Cardiology Research Institute, Tomsk National Research Medical Center

🇷🇺

Tomsk, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath